Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring

Abstract

Emicizumab prophylaxis was mostly well tolerated, although 50% of patients experienced breakthrough bleeds. Routine TG monitoring is not obligatory, and further studies are warranted in selected patient populations.